In humans, M1 macrophages are typically identified by the surface markers CD86 and CD64 ^[23][24][23,24]; the macrophage receptor with collagenous structure MARCO ^[23][25][26][23,25,26]; C-X-C chemokine ligand (CXCL) 9, 10, 11 (CXCL9, 10, 11) [23]; nitric oxide synthase 2 (NOS2), the suppressor of cytokine signaling 1 (SOCS1); and secretion of IL-6, IL-12, IL-1α [27], and TNF-α [24]. M2 macrophages typically express the surface markers CD206 ^{[23][24][25][28][29]}[23,24,25,28,29] and CD163 ^[23][29][23,29] and express/secrete transforming growth factor-beta (TGF-β), peroxisome proliferator-activated receptor gamma (PPARγ), C-C motif chemokine ligands 14 and 22 (CCL14 and CCL22) [28], and arginase-1 (ARG-1) (Table 1) ^[18][22][18,22].

While most macrophage markers are the same in both humans and mice, some exceptions exist. Murine M1 macrophages express macrophage receptors with collagenous structures (Marco) ^[23][25][26][23,25,26], Cxcl9, Cxcl10, Cxcl11 [23], Nos2, and Socs1, and secrete Il-6, Il-12, Il-1α [27], and Tnf-α [24], all comparable to their human counterparts. Murine M1 macrophages do not express surface markers CD86 or CD64. Murine M2 macrophages typically express the surface markers Cd206 ^{[17][18][19][21][22]}[17,18,19,21,22] and Cd163 ^[23][29][23,29] and express/secrete Tgf-β, Pparγ, Ccl14 and Ccl22 [28], and Arg-1 ^[24][29][24,29], similar to human M2 macrophages; however, they also have Chitinase-3-like protein 3 (Chil3), unique from human M2 macrophages (Table 1) [29].

M1 macrophages are pro-inflammatory in nature and are characterized by their high capacity to present antigens, produce interleukin 12 and 23 (IL-12 and IL-23) [33], and activate type-I T-cell responses [5]. They inhibit cell proliferation and cause tissue damage through the secretion of pro-inflammatory cytokines and nitric oxide (NO) and are induced by T-helper type-1 cytokines including interferon-γ (IFN-γ), interleukin-1β (IL-1β), and lipopolysaccharide (LPS) ^{[1][3][4][34]}[1,3,4,34]. M2 macrophages are typically anti-inflammatory in nature and are characterized by their poor ability to present antigen; having low IL-12 and high IL-10, IL-4, and IL-13 secretory profiles; and immunosuppressive effects [5]. These cells promote cell proliferation, tissue repair, angiogenesis, and phagocytosis to downregulate inflammation and “clean up” after inflammatory events and are T-helper type-2 activators and TH1 inhibitors ^{[1][3][4][5][34]}[1,3,4,5,34]. While macrophage polarization is often defined as a specific moment in time, it is important to note that these markers are often present on many subtypes of macrophages in varying expression levels. For example, M2 macrophages can still express M1 markers but with lower levels than M1 macrophages, and vice versa [35].

Extrinsic polarization is a primary method of macrophage polarization and is mediated by cytokine secretion by other cells such as CD4⁺ T_H1 or T_H2 cells (Table 2). Some non-cytokine, extrinsic pathways of macrophage polarization do exist, however, including hypoxia as well as the production of lactate within tumors, which drive M2 polarization [36].

To detail Table 2 and Figure 2, T_H1 cells secrete IFN-γ, which drives polarization of macrophages towards an M1 phenotype, while T_H2 cells secrete IL-4 and IL-13, which drive M2-phenotype polarization ^[34][37][34,37]. IL-4 and IL-13 inhibit the production of nitric oxide, an inflammatory mediator, through the depletion of arginine, which serves as the substrate for iNOS/Nos2. This inhibition of NO production in macrophages was found to be dependent on IL-4 or IL-13 through the depletion of Arg-1 through a Stat6-dependent pathway [38]. This inhibition of NO production leads to a loss of the M1 phenotype and polarization toward the M2 phenotype through cytokines IL-4 and IL-13. IL-4 and LPS signaling can also target the mechanistic target of rapamycin (mTOR) and Akt to trigger polarization. In LPS-mediated M1 polarization, Toll-like receptor 4 (TLR4) activates phosphoinositide 3-kinase (PI3K) followed by Akt and mammalian target of rapamycin complex 1 (mTORC1) activation, leading to M1 polarization ^[39][40][39,40]. Additionally, pharmacological and genetic inhibition of Akt1/2 has shown that Akt1 inhibits M1 activation, and Akt2 leads to the activation of M1 genes, favoring polarization to the M1 phenotype ^[39][40][39,40]. Akt signaling is likely to control macrophage polarization through downstream effectors; for example, Akt signaling inhibits transcription factor Foxo1, which is a key gene in M1 macrophages. Additionally, Akt1 has been implicated as a negative regulator of the nuclear factor, kappa-light-chain-enhanced activity of activated B cells (NF-κB), while Akt2 is a positive regulator. NF-κB is a master regulator of M1 activation [41]. Src homology region 2 domain-containing phosphatase 1/2 (SHP-1/2) inhibits CD11b activity, therefore inhibiting M2 polarization and leading to an increase in M1-type macrophages [42]. Src homology 2 (SH2) domain-containing inositol polyphosphate 5-phosphatase (SHIP) is another phosphatase that inhibits the activation of M2-like macrophages. SHIP^−/− peritoneal and alveolar macrophages have been found to be profoundly M2-skewed, with high arginase I levels and impaired LPS-stimulated NO production [43]. Phosphatase and tensin homolog (PTEN) plays a key role in regulating the inflammatory response through M1-polarization. Mice with a myeloid-specific PTEN knockout have been shown to have levels of M2 macrophages and produce lower TNF-α and higher IL-10 in response to TLR ligands, indicating that PTEN plays a key role in M1 macrophage differentiation [44]. Tumor necrosis factor (TNF) has been found to be a positive regulator of M1 polarization through its activation of the NF-κB pathway. Tumor necrosis factor receptor (TNFR) signaling was found to be a negative regulator of M2 polarization in tumor-associated macrophages (TAMs), and myeloid differentiation primary response 88 (MyD88) was shown to suppress M2 gene expression in TAMs, leading to an M1 phenotype [45].